search

Cue Biopharma (CUE)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA
Sep 22, 2026

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA

Cue Biopharma (CUE) is being initiated with a 'Buy' rating due to positive phase 2 trial results for CUE-221 in chronic spontaneous urticaria (CSU). CUE-221, with its novel dual mechanism of action, showed superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution. Upcoming catalysts include 36-week PK and IgE data in 2026 and planned global phase 2b/3 studies, though the company faces a limited cash runway despite recent financing.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish